Modulators of glucocorticoid receptor, AP-1, and/or...

Details Modulators of glucocorticoid receptor, AP-1, and/or... Modulators of glucocorticoid receptor, AP-1, and/or...

2007-08-08

2011-10-11

Desai, Rita (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S089000, C514S291000

Reexamination Certificate

active

08034940

ABSTRACT:
Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I):an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which:Z is heterocyclo or heteroaryl;A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring;B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R5, R6, R7, and R8;J1, J2, and J3are at each occurrence the same or different and are independently -A1QA2-; Q is a bond, O, S, S(O), or S(O)2; A1and A2are the same or different and are at each occurrence independently selected from a bond, C1-3alkylene, substituted C1-3alkylene, C2-4alkenylene, and substituted C2-4alkenylene, provided that A1and A2are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring;R1to R11are as defined herein.Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

REFERENCES:
patent: 5453421 (1995-09-01), Atwal et al.
patent: 5563169 (1996-10-01), Yoshida et al.
patent: 5776932 (1998-07-01), Schindler et al.
patent: 196 10 882 (1997-09-01), None
patent: 0 301 729 (1989-02-01), None
patent: 0 345 428 (1989-12-01), None
patent: 0 438 869 (1991-07-01), None
patent: 440225787 (1969-10-01), None
patent: 2007-169270 (2007-07-01), None
patent: WO 93/06096 (1993-04-01), None
patent: WO 96/08475 (1996-03-01), None
patent: WO 98/15546 (1998-04-01), None
patent: WO 98/35944 (1998-08-01), None
patent: WO 99/33786 (1999-07-01), None
patent: WO 00/69810 (2000-11-01), None
patent: WO 03/049702 (2003-06-01), None
patent: WO 2004/056744 (2004-07-01), None
patent: WO 2005/066153 (2005-07-01), None
patent: WO 2005/066161 (2005-07-01), None
patent: WO 2005/115977 (2005-12-01), None
patent: WO 2006/053342 (2006-05-01), None
patent: WO 2006/076509 (2006-07-01), None
patent: WO2008/057856 (2008-05-01), None
patent: WO2008/057857 (2008-05-01), None
patent: WO2008/057859 (2008-05-01), None
patent: WO2008/057862 (2008-05-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Database Caplus [Online] Chemical Abstracts Service, Columbus, Ohio, US; Jul. 5, 2007, XP002470068 retrieved from STN Database Accession No. 2007:726515 abstract.
Database Caplus [Online] Chemical Abstracts Service, Columbus, Ohio, US; Feb. 20, 2002, XP002470069 retrieved from STN Database Accession No. 2002:130851 abstract.
Database Caplus [Online] Chemical Abstracts Service, Columbus, Ohio, US; May 12, 1984, XP002470070 retrieved from STN Database Accession No. 1978:62329 abstract.
Database Caplus [Online] Chemical Abstracts Service, Columbus, Ohio, US; May 12, 1984, XP002470071 retrieved from STN Database Accession No. 1970:109347 abstract.
Khan, M.A.J.A. et al., “Synthesis of Some New Tetrahydrocarbazole Derivatives as Possible Antibacterial Agents”, Indian Journal of Heterocyclic Chemistry, vol. 11, pp. 111-114 (2001).
Latif, N. et al., “Cyano Esters and Malononitriles, IV. Cyano(fluorenyl)acetohydrazides and Fluorenylpyrazolones”, Aust. J. Chem., vol. 30, pp. 2255-2262 (1977).
Lewis, A. et al., “Semisynthetic Cephalosporins. II. Structure-Activity Studies in 7-Acylaminocephalosporanic Acids Derived from Dicarboxylic Acids”, Antimicrobial Agents and Chemotherapy, pp. 109-114 (1969).
Database Caplus [Online] Chemical Abstracts Service, Columbus, Ohio, US; May 12, 1984, XP002470072 retrieved from STN Database Accession No. 1970:12746 abstract.
CAS Reg. No. 18435-91-1.
CAS Reg. No. 18435-92-2.
CAS Reg. No. 18435-93-3.
CAS Reg. No. 18435-94-4.
CAS Reg. No. 18435-95-5.
CAS Reg. No. 26133-54-0.
CAS Reg. No. 150330-13-5.
CAS Reg. No. 150330-14-6.
CAS Reg. No. 172729-90-7.
CAS Reg. No. 312522-39-7.
CAS Reg. No. 339283-73-7.
CAS Reg. No. 341936-31-0.
CAS Reg. No. 345990-49-0.
CAS Reg. No. 360572-06-1.
CAS Reg. No. 606096-43-9.
CAS Reg. No. 606096-44-0.
CAS Reg. No. 606096-45-1.
CAS Reg. No. 690647-57-5.
CAS Reg. No. 696604-11-2.
CAS Reg. No. 863437-19-8.
Baldwin, Jr., A.S., “The transcription factor NF-κB and human disease”, The Journal of Clinical Investigation, vol. 107, No. 1, pp. 3-6 (2001).
Burke, J.R., “Targeting IκB kinase for the treatment of inflammatory and other disorders”, Current Opinion in Drug Discovery & Development, vol. 6, No. 5, pp. 720-728 (2003).
Caldenhoven, E. et al., “Negative Cross-Talk between RelA and the Glucocorticoid Receptor: A Possible Mechanism for the Antiinflammatory Action of Glucocorticoids”, Molecular Endocrinology, vol. 9, No. 4, pp. 401-412 (1995).
Chakravarti, D. et al., “Role of CBP/P300 in nuclear receptor signalling”, Nature, vol. 383, pp. 99-103 (1996).
Diamond, M.I. et al., “Transcription Factor Interactions: Selectors of Positive or Negative Regulation from a Single DNA Element”, Science, vol. 249, pp. 1266-1272 (1990).
Evdokimoff, V. et al., “9-Substituted xanthene derivatives”, Annali di Chimica (Rome, Italy), vol. 57, No. 12, pp. 1520-1532 (1967).
Firestein, G.S. et al., “Signal Transduction and Transcription Factors in Rheumatic Disease”, Arthritis & Rheumatism, vol. 42, No. 4, pp. 609-621 (1999).
Jonat, C. et al., “Antitumor Promotion and Antiinflammation: Down-Modulation of AP-1 (Fos/Jun) Activity by Glucocorticoid Hormone”, Cell, vol. 62, pp. 1189-1204 (1990).
Kamei, Y. et al., “A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors”, Cell, vol. 85, pp. 403-414 (1996).
Manning, A.M., et al., “Targeting JNK for Therapeutic Benefit: from Junk to Gold?”, Nature, vol. 2, pp. 554-565 (2003).
Miesfeld, R. et al., “Characterization of a steroid hormone receptor gene and mRNA in wild-type and mutant cells”, Nature, vol. 312, pp. 779-781 (1984).
Peitz, G., “Transcription factors in immune-mediated disease”, Current Opinion in Biotechnology, vol. 8, pp. 467-473 (1997).
Reichardt, H.M. et al., “DNA Binding of the Glucocorticoid Receptor is Not Essential for Survival”, Cell, vol. 93, pp. 531-541 (1998).
Reichardt, H.M. et al., “Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor”, The EMBO Journal, vol. 20, No. 24, pp. 7168-7173 (2001).
Weinberger, C. et al., “Domain structure of human glucocorticoid receptor and its relationship to the v-erb-Aoncogene product”, Nature, vol. 318, pp. 670-672 (1985).
Weinberger, C. et al., “Identification of Human Glucocorticoid Receptor Complementary DNA Clones by Epitope Selection”, Science, vol. 228, pp. 740-742 (1985).
Yang-Yen, H.-F. et al., “Transcriptional Interference between c-Jun and the Glucocorticoid Receptor: Mutual Inhibition of DNA Binding Due to Direct Protein-Protein Interaction”, Cell, vol. 62, pp. 1205-1215 (1990).

Affiliated with

Also associated with

Rating

Modulators of glucocorticoid receptor, AP-1, and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulators of glucocorticoid receptor, AP-1, and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of glucocorticoid receptor, AP-1, and/or... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4271535